Hardman Johnston Global Advisors LLC Genmab A/S Transaction History

Hardman Johnston Global Advisors LLC

$1.97 Billion
Q1 2025

A detailed history of Hardman Johnston Global Advisors LLC transactions in Genmab A/S stock. As of the latest transaction made, Hardman Johnston Global Advisors LLC holds 226,911 shares of GMAB stock, worth $4.8 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

226,911

Previous 214,472 5.8%

Holding current value

$4.8 Million

Previous $4.48 Million 0.76%

% of portfolio

0.23%

Previous 0.2%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$18.69 - $24.14 $232,484 - $300,277	12,439 Added 5.8%	226,911 $4.44 Million
Q4 2024 Feb 04, 2025	SELL	$20.02 - $24.15 $270,009 - $325,711	-13,487 Reduced 5.92%	214,472 $4.48 Million
Q3 2024 Oct 30, 2024	SELL	$23.84 - $28.48 $149,309 - $178,370	-6,263 Reduced 2.67%	227,959 $5.56 Million
Q2 2024 Aug 14, 2024	SELL	$25.13 - $30.27 $710,349 - $855,642	-28,267 Reduced 10.77%	234,222 $5.89 Million
Q1 2024 May 06, 2024	SELL	$26.43 - $32.77 $5.82 Million - $7.21 Million	-220,168 Reduced 45.62%	262,489 $7.85 Million
Q4 2023 Jan 29, 2024	SELL	$27.94 - $35.44 $3.06 Million - $3.89 Million	-109,661 Reduced 18.51%	482,657 $15.4 Million
Q3 2023 Oct 20, 2023	SELL	$35.27 - $42.24 $1.06 Million - $1.27 Million	-30,089 Reduced 4.83%	592,318 $20.9 Million
Q2 2023 Aug 11, 2023	BUY	$37.4 - $42.94 $1.39 Million - $1.6 Million	37,268 Added 6.37%	622,407 $23.7 Million
Q1 2023 May 05, 2023	SELL	$34.88 - $43.22 $692,123 - $857,614	-19,843 Reduced 3.28%	585,139 $22.1 Million
Q4 2022 Feb 03, 2023	SELL	$33.8 - $47.06 $8.1 Million - $11.3 Million	-239,627 Reduced 28.37%	604,982 $25.6 Million
Q3 2022 Nov 02, 2022	SELL	$31.52 - $373.61 $2.8 Million - $33.2 Million	-88,840 Reduced 9.52%	844,609 $27.1 Million
Q2 2022 Aug 02, 2022	SELL	$26.83 - $38.57 $1.3 Million - $1.88 Million	-48,638 Reduced 4.95%	933,449 $30.3 Million
Q1 2022 May 12, 2022	SELL	$30.95 - $39.68 $797,179 - $1.02 Million	-25,757 Reduced 2.56%	982,087 $35.5 Million
Q4 2021 Jan 26, 2022	SELL	$35.87 - $47.12 $2.56 Million - $3.37 Million	-71,425 Reduced 6.62%	1,007,844 $39.9 Million
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $416,040 - $487,833	10,013 Added 0.94%	1,079,269 $47.2 Million
Q2 2021 Aug 09, 2021	BUY	$32.88 - $44.57 $11.6 Million - $15.7 Million	352,610 Added 49.2%	1,069,256 $43.7 Million
Q1 2021 May 12, 2021	SELL	$30.92 - $44.4 $10.6 Million - $15.2 Million	-343,330 Reduced 32.39%	716,646 $23.5 Million
Q4 2020 Feb 11, 2021	BUY	$33.66 - $40.76 $248,410 - $300,808	7,380 Added 0.7%	1,059,976 $43.1 Million
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $12.2 Million - $14.2 Million	367,480 Added 53.64%	1,052,596 $38.5 Million
Q2 2020 Jul 23, 2020	BUY	$20.05 - $33.89 $13.7 Million - $23.2 Million	685,116 New	685,116 $23.2 Million

Others Institutions Holding GMAB

# of Institutions

248

Shares Held

66.2M

Call Options Held

729K

Put Options Held

398K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.9B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hardman Johnston Global Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hardman Johnston Global Advisors LLC with notifications on news.

Account

Hardman Johnston Global Advisors LLC Genmab A/S Transaction History